Floatz logo

TAMOXIFEN

Hot Flushes

Alliance for Clinical Trials in OncologySmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hot Flushes cohort.

Asset / SponsorPhaseRating
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Northwestern University
Phase 2B
Fezolinetant
Shehzad Basaria, M.D.
Phase 2CCC

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →